A Comprehensive Monograph on Cinacalcet (DB01012): Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Cinacalcet represents a seminal achievement in the pharmacological management of mineral metabolism disorders, establishing the drug class of calcimimetics. As a first-in-class, orally administered small molecule, its primary function is as a positive allosteric modulator of the Calcium-Sensing Receptor (CaSR). This novel mechanism of action allows for the direct suppression of parathyroid hormone (PTH) secretion by increasing the sensitivity of the parathyroid gland to extracellular calcium. Consequently, cinacalcet effectively and simultaneously reduces serum levels of PTH, calcium, and phosphorus, a unique therapeutic profile that distinguishes it from other agents used in this field, such as vitamin D sterols.

The principal clinical indications for cinacalcet include the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on dialysis, the management of hypercalcemia in patients with parathyroid carcinoma, and the treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are not candidates for parathyroidectomy. Its pharmacokinetic profile is characterized by rapid but variable oral absorption that is significantly enhanced by food, extensive protein binding, a long terminal half-life of 30-40 hours, and complex hepatic metabolism primarily via cytochrome P450 (CYP) enzymes CYP3A4, CYP2D6, and CYP1A2. Critically, cinacalcet is also a potent inhibitor of CYP2D6, creating a high potential for clinically significant drug-drug interactions.

The primary safety concern associated with cinacalcet therapy is an exaggeration of its pharmacologic effect, leading to hypocalcemia, which can manifest with symptoms ranging from paresthesias to life-threatening seizures and cardiac arrhythmias. This risk necessitates a cautious dose-titration strategy and rigorous monitoring of serum calcium levels. The most common adverse effects are gastrointestinal in nature, including nausea and vomiting.

Developed by Amgen under license from NPS Pharmaceuticals, cinacalcet was approved by major regulatory bodies in 2004 under the brand names Sensipar® in North America and Mimpara® in Europe. While it has become a cornerstone of therapy for severe hyperparathyroidism, the therapeutic landscape has evolved with the introduction of the intravenous calcimimetic etelcalcetide, which offers advantages in adherence and PTH-lowering efficacy. Nevertheless, with the availability of generic formulations, cinacalcet remains a vital and cost-effective therapeutic tool, provided clinicians maintain a thorough understanding of its complex pharmacology, safety profile, and interaction potential.

Drug Identification and Physicochemical Properties

A precise understanding of the chemical and physical characteristics of a therapeutic agent is fundamental to appreciating its formulation, pharmacology, and clinical behavior. Cinacalcet is a synthetic, small molecule compound with a distinct chemical structure that dictates its function as a calcimimetic agent.

Nomenclature and Identifiers

Cinacalcet is systematically identified across various chemical and pharmacological databases to ensure unambiguous reference. Its primary identifiers are as follows:

• International Nonproprietary Name (INN): Cinacalcet [1]
• DrugBank Accession Number: DB01012 [1]
• Drug Type: Small Molecule [2]
• CAS Number: 226256-56-0 (for the free base); 364782-34-3 (for the hydrochloride salt) [1]
• IUPAC Name: N--3-[3-(trifluoromethyl)phenyl]propan-1-amine. The designation of the (R)-stereoisomer is critical, as this is the pharmacologically active enantiomer.[1]
• Common Synonyms and Brand Names: Sensipar® (North America, Australia), Mimpara® (Europe), and the development code AMG-073.[1]

Chemical Structure and Properties

The molecular structure of cinacalcet is central to its ability to interact with the Calcium-Sensing Receptor.

• Chemical Formula: C22​H22​F3​N [1]
• Molar Mass: 357.41 g·mol⁻¹ [2]
• Chemical Descriptors:
• SMILES: C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F [3]
• InChI: InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24,25)/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1 [1]
• InChIKey: VDHAWDNDOKGFTD-MRXNPFEDSA-N [1]

Physical Characteristics

The physical properties of cinacalcet, particularly its solubility, have significant implications for its clinical use and formulation.

• Appearance: The hydrochloride salt is described as a white to off-white crystalline solid.[7] Some suppliers may list the free base as a liquid.[4]
• Solubility: Cinacalcet hydrochloride is slightly soluble in water but soluble in organic solvents such as methanol, 95% ethanol, and DMSO.[4]
• Biopharmaceutics Classification System (BCS): Cinacalcet is classified as a BCS Class 4 drug, characterized by both low aqueous solubility and low intestinal permeability.[8]

This BCS Class 4 designation is a critical determinant of its pharmacokinetic behavior. Drugs in this class present significant formulation challenges for oral delivery because both their rate of dissolution in the gastrointestinal fluids and their ability to permeate the intestinal wall are limited, leading to inherently low and variable bioavailability. This fundamental physicochemical property directly explains the profound food effect observed with cinacalcet, where co-administration with a high-fat meal can increase its absorption by up to 82%.[7] The presence of fats and bile salts in the gut lumen during digestion aids in the solubilization of the lipophilic cinacalcet molecule, thereby increasing the concentration of dissolved drug available for absorption across the intestinal epithelium. This mechanistic link between its poor solubility and food-dependent absorption underpins the strict clinical directive that cinacalcet must be administered with food to ensure more consistent and therapeutically adequate systemic exposure.[10]

Table 1: Physicochemical and Database Identifiers for Cinacalcet
Property/Identifier	Value/Code
DrugBank ID	DB01012 1
CAS Number (free base)	226256-56-0 1
CAS Number (HCl salt)	364782-34-3 3
Chemical Formula	C22​H22​F3​N 1
Molar Mass	357.41 g·mol⁻¹ 2
IUPAC Name	N--3-[3-(trifluoromethyl)phenyl]propan-1-amine 3
PubChem CID	156419 1
ChEBI ID	CHEBI:48390 1
KEGG ID	D03504 1
SMILES	C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F 3
InChIKey	VDHAWDNDOKGFTD-MRXNPFEDSA-N 1
BCS Class	Class 4 8

Pharmacology: Mechanism of Action and Pharmacodynamics

Cinacalcet's therapeutic effects are derived from its unique interaction with the Calcium-Sensing Receptor, a key regulator of mineral homeostasis. Its development marked a significant advancement in pharmacology as the first clinically approved allosteric modulator of a G-protein coupled receptor (GPCR).[12]

The Calcium-Sensing Receptor (CaSR) as a Therapeutic Target

The CaSR is a member of the Class C family of GPCRs, characterized by a large extracellular domain that functions as a "Venus flytrap" to bind its endogenous ligand, extracellular calcium (Ca2+).[12] The CaSR is expressed in various tissues, but its most prominent physiological role is in the parathyroid gland.[12] On the surface of parathyroid chief cells, the CaSR serves as the primary negative regulator of PTH synthesis and secretion.[1] When extracellular calcium levels rise, calcium binds to and activates the CaSR, initiating intracellular signaling cascades (primarily through

Gq/11​ and Gi/o​ proteins) that inhibit the release of pre-formed PTH from secretory granules and suppress the transcription of the PTH gene.[12] This negative feedback loop is essential for maintaining serum calcium within a very narrow physiological range. In disease states like hyperparathyroidism, this regulatory system is dysfunctional, leading to excessive PTH secretion.

Cinacalcet as a Positive Allosteric Modulator (PAM)

Cinacalcet is classified as a calcimimetic, a substance that mimics the action of calcium on the CaSR.[1] More specifically, it functions as a Type II positive allosteric modulator. Unlike a direct agonist, cinacalcet does not activate the CaSR on its own. Instead, it binds to a distinct allosteric site located within the seven-transmembrane (7TM) domain of the receptor, separate from the orthosteric calcium-binding site in the extracellular domain.[12]

The binding of cinacalcet to this allosteric site induces a conformational change in the receptor that greatly increases its affinity for extracellular calcium.[1] This allosteric potentiation means that the receptor becomes activated at a lower concentration of ambient calcium than would normally be required. In a clinical context, this enhanced sensitivity effectively resets the calcium-PTH feedback loop, causing the parathyroid gland to perceive the patient's existing serum calcium level as being higher than it actually is, thereby leading to a profound suppression of PTH secretion.[13]

A more sophisticated understanding of cinacalcet's action involves the concept of biased signaling. The CaSR can activate multiple intracellular pathways, and allosteric modulators can preferentially enhance signaling through one pathway over another.[14] Evidence suggests that cinacalcet exhibits such stimulus bias, showing greater potentiation of intracellular calcium mobilization (a

Gq​-mediated pathway critical for PTH suppression) relative to other pathways like ERK1/2 phosphorylation.[19] This selective enhancement of the therapeutically relevant signaling cascade within the parathyroid gland may contribute to its clinical efficacy and therapeutic window, allowing for a more targeted effect despite the widespread expression of the CaSR in other tissues.

Pharmacodynamic Effects on Mineral Metabolism

The allosteric modulation of the CaSR by cinacalcet translates into a cascade of predictable and measurable pharmacodynamic effects.

• Parathyroid Hormone Suppression: The primary and most immediate effect of cinacalcet is a rapid, dose-dependent reduction in circulating PTH levels.[2] The nadir of PTH concentration is typically observed 2 to 6 hours after oral administration, a timeframe that corresponds directly with the peak plasma concentration ( Cmax​) of the drug.[9] This tight correlation between drug exposure and PTH response is a hallmark of its direct mechanism.
• Serum Calcium and Phosphorus Reduction: As a direct consequence of PTH suppression, serum calcium levels decrease.[1] Lower PTH levels lead to reduced calcium resorption from bone, decreased renal tubular reabsorption of calcium, and lower production of active vitamin D (calcitriol), which in turn reduces intestinal calcium absorption. In clinical trials, cinacalcet has also been consistently shown to lower serum phosphorus levels, an effect that contributes to better overall control of mineral metabolism in CKD patients.[13]
• Time-Course of Action: In patients on a stable daily dose, the PTH-lowering effect is transient within a 24-hour dosing interval. Studies have shown that after a morning dose, PTH levels are significantly reduced for 1 to 6 hours but return to pre-dose baseline levels by 24 hours.[20] This pharmacodynamic profile underscores the necessity of consistent, once-daily administration to maintain therapeutic control over the full dosing period. Furthermore, upon discontinuation of the drug, a rebound effect is observed, with PTH levels rising significantly above baseline within 48 hours, highlighting the drug's role in actively suppressing an underlying pathological drive for PTH secretion.[20]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical utility and safety of cinacalcet are heavily influenced by its pharmacokinetic profile, which describes its journey through the body. Its ADME characteristics are complex, featuring food-dependent absorption, extensive metabolism, and a significant potential for drug-drug interactions.

Absorption and Bioavailability

Cinacalcet is administered orally and is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations (Cmax​) are typically reached within 2 to 6 hours following administration.[9] The absorption process is profoundly influenced by the presence of food. As a BCS Class 4 drug with low solubility and permeability, its bioavailability is limited under fasting conditions.[8] Administration with a high-fat meal dramatically increases both the rate and extent of absorption, boosting

Cmax​ by 82% and the total exposure (Area Under the Curve, AUC) by 68% compared to the fasting state. A low-fat meal produces a similar, though slightly less pronounced, effect.[7] This significant food effect makes co-administration with a meal a clinical necessity to ensure consistent and adequate drug exposure. The absolute bioavailability of cinacalcet, even with food, is modest, estimated to be between 20% and 25%.[9]

Distribution

Following absorption, cinacalcet is distributed extensively throughout the body, as indicated by its large apparent volume of distribution (Vd​) of approximately 1000 L.[8] This suggests significant partitioning of the drug from the plasma into various tissues. Cinacalcet is also highly bound to plasma proteins, with a binding fraction of 93% to 97%.[2] This high degree of protein binding means that only a small fraction of the drug in circulation is free (unbound) and pharmacologically active.

Metabolism

Cinacalcet undergoes extensive hepatic metabolism, with less than 1% of the parent drug excreted unchanged in the urine.[9] The metabolism is complex, involving multiple cytochrome P450 (CYP) isoenzymes. The primary pathways are mediated by

CYP3A4, CYP2D6, and CYP1A2.[1] The main metabolic transformations are oxidative N-dealkylation, which forms hydrocinnamic acid derivatives, and oxidation of the naphthalene ring structure to form dihydrodiols.[7] These primary metabolites are subsequently conjugated with glycine or glucuronic acid before excretion. Importantly, these major circulating metabolites possess minimal or no calcimimetic activity, meaning the pharmacological effect is driven almost entirely by the parent compound.[8]

A crucial aspect of its metabolic profile is that cinacalcet itself is a strong inhibitor of CYP2D6.[1] This dual role—as a substrate for multiple CYP enzymes and a potent inhibitor of one—creates a complex and clinically significant potential for drug-drug interactions. Its own plasma concentrations can be altered by inhibitors or inducers of CYP3A4, CYP2D6, and CYP1A2. Simultaneously, it can dramatically increase the plasma concentrations of other drugs that are dependent on CYP2D6 for their clearance. This bidirectional interaction profile requires careful clinical management and medication review when cinacalcet is prescribed.

Elimination

The elimination of cinacalcet is characterized by a long terminal half-life (t1/2​) of 30 to 40 hours.[8] This long half-life allows for once-daily dosing, with steady-state plasma concentrations typically achieved within 7 days of initiating or changing a dose.[9] The primary route of elimination is via the kidneys, with approximately 80% of the administered dose being recovered in the urine as metabolites. A smaller portion, around 15%, is eliminated in the feces.[2]

Pharmacokinetics in Special Populations

• Renal Impairment: The pharmacokinetics of cinacalcet are not significantly affected by the degree of renal impairment, from mild insufficiency to end-stage renal disease requiring dialysis. Hemodialysis and peritoneal dialysis do not appreciably alter its clearance. Consequently, no dose adjustment is necessary based on renal function.[7]
• Hepatic Impairment: Liver function has a substantial impact on cinacalcet clearance. In patients with moderate hepatic impairment, drug exposure (AUC) is increased by approximately 2-fold, while in severe hepatic impairment, it is increased by over 4-fold. The elimination half-life is also prolonged. Therefore, patients with moderate to severe hepatic impairment require close monitoring of PTH and serum calcium levels during treatment.[9]
• Other Factors: Pharmacokinetic analyses have identified minor differences based on sex and smoking status, with females showing lower clearance and smokers showing higher clearance. However, these variations are not considered clinically significant because the dose of cinacalcet is individually titrated based on biochemical response (PTH levels) rather than on fixed dosing schemes.[8]

Table 2: Summary of Cinacalcet Pharmacokinetic Parameters
Parameter	Value/Description
Time to Peak (Tmax​)	2–6 hours 9
Bioavailability	20–25% (with food) 9
Food Effect	AUC increased by 68% with a high-fat meal 8
Volume of Distribution (Vd​)	~1000 L 8
Plasma Protein Binding	93–97% 2
Terminal Half-Life (t1/2​)	30–40 hours 8
Metabolizing Enzymes	CYP3A4, CYP2D6, CYP1A2 (primary) 1
CYP Inhibition Profile	Strong inhibitor of CYP2D6 1
Route of Elimination	~80% renal (as metabolites), ~15% fecal 2

Clinical Applications, Dosing, and Efficacy

Cinacalcet is indicated for specific disorders of the parathyroid gland and calcium metabolism where excessive PTH secretion is the primary pathological driver. Its use requires careful patient selection, individualized dose titration, and regular biochemical monitoring.

Approved Indications and Therapeutic Rationale

Cinacalcet is approved by major regulatory bodies for the following conditions in adults:

• Secondary Hyperparathyroidism (SHPT) in Patients with Chronic Kidney Disease (CKD) on Dialysis: This is the most common indication. In patients with end-stage renal disease (ESRD), impaired phosphate excretion and reduced active vitamin D synthesis lead to compensatory, but ultimately maladaptive, overproduction of PTH. This results in CKD-Mineral and Bone Disorder (CKD-MBD), characterized by high-turnover bone disease (renal osteodystrophy), vascular calcification, and increased cardiovascular morbidity and mortality. Cinacalcet directly targets the overactive parathyroid gland to lower PTH, thereby helping to normalize mineral metabolism.[1] A crucial Limitation of Use exists for this indication: cinacalcet is not approved for patients with CKD who are not on dialysis, due to a significantly increased risk of hypocalcemia in this population.[10]
• Hypercalcemia in Patients with Parathyroid Carcinoma: Parathyroid carcinoma is a rare malignancy characterized by the uncontrolled and autonomous secretion of massive amounts of PTH, leading to severe and often life-threatening hypercalcemia. While surgery is the primary treatment, cinacalcet serves as a vital pharmacological tool to control serum calcium levels in patients with unresectable, recurrent, or metastatic disease.[1]
• Severe Hypercalcemia in Patients with Primary Hyperparathyroidism (PHPT): PHPT is typically caused by a benign parathyroid adenoma. The definitive treatment is surgical removal of the affected gland (parathyroidectomy). Cinacalcet is indicated for patients with severe hypercalcemia due to PHPT who are unable to undergo surgery because of medical contraindications or other factors.[1]
• Pediatric Use: In the European Union, a pediatric formulation of cinacalcet is approved for treating SHPT in children aged three years and older with ESRD on maintenance dialysis.[1] However, cinacalcet is not approved for any pediatric use in the United States. Pediatric clinical trials in the U.S. were suspended by the FDA following the death of a 14-year-old patient associated with severe hypocalcemia, highlighting the heightened risks in this population.[1]

Dosage and Administration

Proper administration and careful dose titration are essential for the safe and effective use of cinacalcet.

• General Administration: All doses should be taken orally with food or shortly after a meal to maximize absorption. The tablets must be swallowed whole and should not be split, chewed, or crushed.[10]
• Dosing Regimens: The starting dose and titration schedule vary by indication, as summarized in Table 3. The guiding principle is to "start low and titrate slow" based on regular monitoring of biochemical parameters.

Table 3: Dosing and Titration Schedules by Indication
Indication	Starting Dose	Titration Schedule	Maximum Dose	Therapeutic Target
Secondary HPT in CKD on Dialysis	30 mg once daily 10	Increase every 2–4 weeks through sequential doses of 60, 90, 120, 180 mg once daily 10	180 mg once daily 10	Intact PTH (iPTH) 150–300 pg/mL 21
Parathyroid Carcinoma / Primary HPT	30 mg twice daily 10	Increase every 2–4 weeks through sequential doses of 60 mg BID, 90 mg BID, and up to 90 mg TID or QID 10	360 mg per day (90 mg QID) 10	Normalize serum calcium levels 21

Monitoring Requirements

Close monitoring is a cornerstone of cinacalcet therapy to ensure efficacy and mitigate the risk of hypocalcemia.

• For SHPT: Serum calcium and phosphorus levels must be measured within one week of initiation or any dose adjustment, and intact PTH should be measured within one to four weeks. Once a stable maintenance dose is established, serum calcium should be checked approximately monthly.[10] It is important to note that for monitoring purposes, blood for iPTH measurement should be drawn at least 12 hours after the last dose to assess the trough level.[21]
• For Parathyroid Carcinoma and Primary HPT: Serum calcium must be measured within one week of initiation or dose adjustment. Once the patient is on a maintenance dose, serum calcium should be monitored every two months.[10]

Summary of Clinical Efficacy

The efficacy of cinacalcet has been established in numerous randomized controlled trials.

• In three pivotal 26-week, phase 3 trials involving over 1,100 dialysis patients with uncontrolled SHPT, cinacalcet was significantly more effective than placebo. A much higher proportion of patients treated with cinacalcet achieved the primary endpoint of a mean iPTH level of 250 pg/mL or less.[13] A key finding was that cinacalcet treatment simultaneously lowered not only PTH but also serum calcium, phosphorus, and the calcium-phosphorus product, addressing multiple facets of CKD-MBD.[13] This efficacy was observed across a broad range of patients, regardless of disease severity, age, sex, race, or concurrent use of vitamin D sterols and phosphate binders.[13]
• In patients with parathyroid carcinoma, an open-label trial demonstrated that cinacalcet reduced serum calcium levels by at least 1 mg/dL in 71% of patients.[13]
• The large-scale EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial randomized 3,883 hemodialysis patients to either cinacalcet or placebo to assess its impact on mortality and major cardiovascular events.[30] In the primary intention-to-treat analysis, the study did not meet its composite primary endpoint. However, prespecified secondary analyses adjusting for baseline characteristics and other factors suggested a potential reduction in cardiovascular events and fractures, though these findings are not considered definitive proof of a cardiovascular benefit.[32]

Safety, Tolerability, and Risk Management

The safety profile of cinacalcet is well-characterized and is largely a direct extension of its potent pharmacologic effects on calcium homeostasis. A thorough understanding of its risks and a proactive management strategy are essential for its safe clinical use.

Contraindications

The use of cinacalcet is strictly contraindicated in the following situations:

• Hypocalcemia: Cinacalcet must not be initiated in patients whose serum calcium is below the lower limit of the normal range. Because the drug's primary action is to lower serum calcium, starting it in a patient who is already hypocalcemic could precipitate a severe and dangerous drop in calcium levels.[1]
• Hypersensitivity: Patients with a known hypersensitivity to cinacalcet or any of the excipients in the tablet formulation should not receive the drug.[23]

Warnings and Precautions

The prescribing information for cinacalcet includes several important warnings that require clinician vigilance.

• Hypocalcemia: This is the most significant and common safety concern. By design, cinacalcet lowers serum calcium. If this reduction is excessive, it can lead to symptomatic hypocalcemia, with potential manifestations including paresthesias (tingling or numbness, especially around the mouth, fingers, and feet), myalgias (muscle aches), muscle cramping, tetany (involuntary muscle spasms), and convulsions (seizures).[1] Life-threatening events and fatal outcomes associated with severe hypocalcemia have been reported, particularly in the pediatric population, which led to the suspension of pediatric trials in the U.S..[23] Management of hypocalcemia involves withholding or reducing the cinacalcet dose and administering calcium supplements, calcium-based phosphate binders, and/or vitamin D sterols to restore normal calcium levels.[21]
• Seizures: Significant reductions in serum calcium lower the convulsive threshold. Clinical trials showed a slightly higher incidence of seizures in patients treated with cinacalcet compared to placebo. Therefore, serum calcium levels should be monitored with particular care in patients with a history of seizure disorders.[21]
• Cardiovascular Effects: Postmarketing surveillance has identified isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or cardiac arrhythmias in patients with pre-existing impaired cardiac function. While a direct causal link has not been definitively established, these events may be mediated by the negative inotropic effects of hypocalcemia.[21] Furthermore, hypocalcemia is known to prolong the QT interval on an electrocardiogram, which can increase the risk of serious ventricular arrhythmias, such as Torsades de Pointes. This risk is heightened in patients with congenital long QT syndrome or those taking other QT-prolonging medications.[23]
• Adynamic Bone Disease: Over-suppression of PTH (typically to levels below 100-150 pg/mL) can lead to adynamic bone disease, a condition of severely reduced bone turnover that increases the risk of fracture and may be associated with vascular calcification. If iPTH levels fall below the target range, the dose of cinacalcet and/or vitamin D sterols should be reduced or discontinued.[21]
• Gastrointestinal (GI) Bleeding: Cases of upper GI bleeding have been reported in patients taking cinacalcet. While the mechanism is unknown, patients with known risk factors such as gastritis, esophagitis, or peptic ulcers may be at increased risk, potentially exacerbated by the common side effects of nausea and vomiting.[23]

The constellation of these major safety concerns can be understood as a direct causal chain originating from the drug's primary mechanism of action. The potentiation of the CaSR leads to the intended therapeutic effect of PTH reduction, but also to the primary on-target adverse effect of hypocalcemia. This hypocalcemia, in turn, is the direct physiological cause of the secondary risks, including a lowered seizure threshold and potential for cardiac arrhythmias. Similarly, an overextension of the therapeutic effect—excessive PTH suppression—leads directly to the risk of adynamic bone disease. This mechanistic linkage provides a clear conceptual framework for risk management: the key to the safe use of cinacalcet is not the avoidance of its on-target effects, but the meticulous monitoring and management of their magnitude.

Adverse Effects Profile

• Common Adverse Effects: The most frequently reported adverse events in clinical trials are gastrointestinal. These include nausea (up to 31% of patients), vomiting (up to 27%), and diarrhea (up to 21%). Other common side effects (≥5% incidence) include myalgia, dizziness, weakness, chest pain, hypertension, asthenia (abnormal weakness), and anorexia (loss of appetite).[1]
• Serious Adverse Effects: Beyond the events listed in the warnings section, serious adverse effects can include severe hypocalcemia, seizures, QT prolongation, ventricular arrhythmia, and rare but serious hypersensitivity reactions such as angioedema and urticaria.[1]

Management of Overdose

An overdose of cinacalcet would be expected to lead to profound hypocalcemia and its associated symptoms.[2] Management is supportive and focuses on monitoring the patient for signs and symptoms of hypocalcemia (e.g., neuromuscular irritability, ECG changes) and correcting serum calcium levels as needed through intravenous or oral calcium administration. Due to its high degree of plasma protein binding (93-97%), cinacalcet is not effectively removed by hemodialysis, making dialysis an ineffective treatment for overdose.[36]

Drug and Food Interactions

The complex metabolism of cinacalcet and its potent inhibitory effect on a key drug-metabolizing enzyme create a high potential for clinically significant drug-drug interactions (DDIs). Additionally, its absorption is highly dependent on food.

Pharmacokinetic Interactions

Pharmacokinetic interactions can be bidirectional: some drugs can alter the concentration of cinacalcet, while cinacalcet can alter the concentration of other drugs.

Effects of Other Drugs on Cinacalcet

Because cinacalcet is a substrate of CYP3A4, CYP2D6, and CYP1A2, its plasma concentration can be significantly altered by drugs that inhibit or induce these enzymes.

• Strong CYP3A4 Inhibitors: Co-administration with potent inhibitors of CYP3A4 can lead to a substantial increase in cinacalcet levels, raising the risk of hypocalcemia. For example, co-administration with ketoconazole (a strong CYP3A4 inhibitor) increased cinacalcet exposure (AUC) by 2.3-fold.[2] Other strong CYP3A4 inhibitors include itraconazole, clarithromycin, and ritonavir. When a patient on cinacalcet initiates therapy with a strong CYP3A4 inhibitor, their PTH and serum calcium levels should be monitored closely, and a dose reduction of cinacalcet may be necessary.[9]
• CYP Inducers: Conversely, co-administration with strong inducers of CYP enzymes, such as rifampin (a potent inducer of CYP3A4 and other CYPs) or the herbal supplement St. John's Wort, could theoretically decrease cinacalcet plasma concentrations and reduce its efficacy. This may necessitate an increase in the cinacalcet dose.[23]

Effects of Cinacalcet on Other Drugs

Cinacalcet is a strong inhibitor of CYP2D6 and therefore can significantly increase the exposure of drugs that are primarily metabolized by this enzyme.[1] This is particularly concerning for CYP2D6 substrates that have a narrow therapeutic index, where a modest increase in concentration can lead to toxicity.

• CYP2D6 Substrates: Clinically important examples include:
• Tricyclic Antidepressants (TCAs): Cinacalcet can more than double the exposure to TCAs like desipramine and amitriptyline, increasing the risk of cardiotoxicity and anticholinergic side effects.[9]
• Antiarrhythmics: For Class 1C antiarrhythmics like flecainide and propafenone, which have a narrow therapeutic index, co-administration with cinacalcet can lead to dangerous increases in concentration and proarrhythmic effects.[9]
• Beta-blockers: Many beta-blockers, such as metoprolol and carvedilol, are metabolized by CYP2D6. Cinacalcet can increase their levels, potentially leading to excessive bradycardia or hypotension.[9]
• Other Drugs: Tamoxifen's conversion to its active metabolite, endoxifen, is CYP2D6-dependent; cinacalcet may decrease its therapeutic effect.[2] Cinacalcet can also increase levels of atomoxetine, aripiprazole, and tolterodine.[2]

Pharmacodynamic Interactions

• Other Calcium-Lowering Drugs: The concurrent use of cinacalcet with other medications known to lower serum calcium can lead to an additive effect and increase the risk of severe hypocalcemia. This requires careful monitoring.[23]
• Etelcalcetide: The co-administration of cinacalcet with etelcalcetide, another calcimimetic, is contraindicated. Both drugs act on the CaSR, and their combined use would result in a synergistic pharmacodynamic effect, leading to a high risk of severe, potentially life-threatening, hypocalcemia.[23] When switching a patient from cinacalcet to etelcalcetide, the cinacalcet must be discontinued for at least seven days before the first dose of etelcalcetide is administered.[25]

Food Interactions

• Food: As established, food significantly enhances the absorption of cinacalcet. It must be taken with a meal or shortly thereafter to ensure consistent bioavailability.[8]
• Grapefruit Juice: Grapefruit and its juice are potent inhibitors of intestinal CYP3A4. Consumption should be avoided during cinacalcet therapy, as it can increase drug exposure and the risk of adverse effects.[37]

Table 4: Clinically Significant Drug-Drug Interactions with Cinacalcet
Interacting Drug/Class	Mechanism of Interaction	Clinical Management/Recommendation
Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)	Inhibition of cinacalcet metabolism, leading to increased cinacalcet exposure.	Monitor PTH and serum calcium closely. A dose reduction of cinacalcet may be required.2
CYP Inducers (e.g., rifampin, St. John's Wort)	Induction of cinacalcet metabolism, potentially leading to decreased cinacalcet exposure and reduced efficacy.	Monitor for loss of efficacy. A dose increase of cinacalcet may be required.23
CYP2D6 Substrates with Narrow Therapeutic Index (e.g., flecainide, TCAs like desipramine)	Strong inhibition of substrate metabolism by cinacalcet, leading to increased substrate exposure and risk of toxicity.	Dose reduction of the concomitant CYP2D6 substrate may be required. Therapeutic drug monitoring, if available, is recommended.2
Etelcalcetide	Pharmacodynamic synergism at the Calcium-Sensing Receptor, leading to a high risk of severe hypocalcemia.	Co-administration is contraindicated. A washout period of at least 7 days is required when switching from cinacalcet to etelcalcetide.23
Grapefruit Juice	Strong inhibition of intestinal CYP3A4, leading to increased cinacalcet absorption and exposure.	Patients should be advised to avoid consuming grapefruit or grapefruit juice during therapy.37

Regulatory and Commercial Landscape

The journey of cinacalcet from a novel chemical entity to a globally marketed therapeutic is a case study in targeted drug development for a specific metabolic disorder.

Development and Approval History

• Originator and Developer: The foundational discovery of calcimimetic compounds, including cinacalcet, was made by scientists at NPS Pharmaceuticals in the early 1990s.[39] Recognizing the therapeutic potential, Amgen Inc. licensed the compounds from NPS in 1996 and undertook the extensive clinical development program required for regulatory approval.[39] Amgen holds the rights for worldwide commercialization, with the exception of Japan and several other Asian territories, where rights were licensed to Kirin Brewery Co Ltd.[39]
• Brand Names: The drug is marketed globally under two primary brand names: Sensipar® in North America and Australia, and Mimpara® in Europe.[1]
• U.S. Food and Drug Administration (FDA) Approval: Amgen submitted its New Drug Application (NDA) for cinacalcet in September 2003.[40] Following a priority review, the FDA granted its initial approval for Sensipar® on March 8, 2004. The initial indications were for the treatment of SHPT in CKD patients on dialysis and for hypercalcemia in patients with parathyroid carcinoma.[43] The label was later expanded in February 2011 to include the treatment of severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy.[38]
• European Medicines Agency (EMA) Approval: Following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in July 2004 [41], the European Commission granted a centralized marketing authorization for Mimpara® on October 22, 2004.[32] The initial indication was for SHPT in dialysis patients. The European label was subsequently expanded to include primary HPT in June 2008 [48] and, notably, for the treatment of SHPT in pediatric patients (aged ≥3 years) on dialysis in 2017.[26]

Formulations and Generic Availability

• Formulations: Cinacalcet is commercially available as light-green, film-coated, oval-shaped tablets in strengths of 30 mg, 60 mg, and 90 mg of the active base.[7] For the pediatric indication in Europe, a formulation of granules in capsules for opening was developed and approved to allow for more precise, weight-based dosing.[26] Clinical trials in pediatric populations also explored the use of sprinkle capsules and liquid suspensions prepared from the capsules.[49]
• Generic Competition: The patents protecting Sensipar® and Mimpara®, held by Amgen, have begun to expire, paving the way for generic competition. In the United States, the first AB-rated generic version of cinacalcet was launched in March 2019.[52] In the European Union, marketing authorizations for generic cinacalcet were granted as early as November 2015.[53] The availability of lower-cost generic versions has broadened access to this therapy, though it also places it in direct competition with newer, patent-protected agents.

Comparative Analysis and Future Perspectives

Cinacalcet's position in clinical practice is best understood by comparing it to alternative therapies and considering the evolving landscape of treatments for hyperparathyroidism.

Head-to-Head Comparison: Cinacalcet vs. Etelcalcetide

The most direct competitor to cinacalcet is etelcalcetide (Parsabiv®), a second-generation calcimimetic. While both drugs target the CaSR, they have key differences in their pharmacology, administration, and clinical profiles.

• Mechanism and Administration: Cinacalcet is an oral, small-molecule allosteric modulator that is administered daily by the patient.[17] Etelcalcetide is a peptide-based direct agonist of the CaSR that is administered intravenously three times per week by healthcare staff at the conclusion of a hemodialysis session.[55] The intravenous route of etelcalcetide bypasses the gastrointestinal tract and ensures 100% adherence in the hemodialysis population, a significant advantage over the oral cinacalcet, which is subject to non-adherence.[56]
• Efficacy: In head-to-head, randomized controlled trials, etelcalcetide demonstrated non-inferiority and subsequently superiority to cinacalcet in achieving target PTH reductions. A significantly greater proportion of patients treated with etelcalcetide achieved both >30% and >50% reductions in PTH compared to those treated with cinacalcet.[4] Real-world observational studies have corroborated these findings, showing that dialysis facilities that switched to an etelcalcetide-first strategy achieved significantly lower mean PTH levels compared to those continuing with cinacalcet.[56]
• Safety and Tolerability: Both drugs share the primary risk of hypocalcemia. Clinical trial data suggest that etelcalcetide is associated with a higher incidence of decreased blood calcium and symptomatic hypocalcemia compared to cinacalcet.[57] Both drugs can cause gastrointestinal side effects like nausea and vomiting. Although etelcalcetide's IV administration avoids direct contact with the GI mucosa, these effects are believed to be systemic and mediated by CaSR activation in other tissues, and thus are still observed with etelcalcetide.[55] However, for patients with severe GI intolerance specifically to the oral formulation of cinacalcet, IV etelcalcetide may be a better-tolerated alternative.[60]

Table 5: Comparative Profile of Cinacalcet vs. Etelcalcetide
Feature	Cinacalcet (Sensipar®/Mimpara®)	Etelcalcetide (Parsabiv®)
Mechanism of Action	Positive Allosteric Modulator of CaSR 17	Direct Agonist of CaSR 55
Route & Frequency	Oral, once daily 10	Intravenous, 3 times per week with dialysis 55
Efficacy (PTH Reduction)	Effective; established as standard of care 13	Superior to cinacalcet in head-to-head trials 57
Key Safety Issues	Hypocalcemia, Nausea, Vomiting 21	Higher incidence of hypocalcemia vs. cinacalcet; Nausea, Vomiting 57
Clinical Considerations	Requires patient adherence; significant food effect; strong CYP2D6 inhibitor with high DDI potential 9	Ensures 100% adherence in HD setting; bypasses GI absorption; fewer pharmacokinetic DDIs 56

Position in the Therapeutic Armamentarium

Cinacalcet occupies a unique and important place in the management of SHPT. Its primary advantage over traditional therapies like active vitamin D sterols (e.g., calcitriol, paricalcitol) is its ability to lower PTH while simultaneously lowering or maintaining stable serum calcium levels.[61] In contrast, vitamin D analogs suppress PTH but invariably tend to increase serum calcium and phosphorus by promoting intestinal absorption, which can limit their use, especially in patients who are already hypercalcemic or hyperphosphatemic.[61] This complementary mechanism allows cinacalcet to be used in combination with vitamin D sterols, often enabling the use of the latter in patients who would otherwise not tolerate them. The standard therapeutic regimen for SHPT often involves a multi-faceted approach combining a calcimimetic, a vitamin D sterol, and phosphate binders.[1] For patients with severe, refractory hyperparathyroidism who fail to respond to maximal medical therapy, surgical parathyroidectomy remains the definitive treatment option.[60]

Ongoing Research and Future Directions

While the pivotal clinical trials for its primary indications have been completed, research involving cinacalcet continues. The large EVOLVE trial provided a wealth of long-term data on cardiovascular outcomes, which continues to be analyzed.[31] There is also ongoing interest in its off-label use for other conditions, such as calciphylaxis, a rare and devastating disorder of vascular calcification seen in some dialysis patients, though its efficacy in this setting is not yet definitively established.[22] The development and success of etelcalcetide have validated the CaSR as a durable therapeutic target and signal a continued effort within the pharmaceutical industry to develop next-generation calcimimetics with improved efficacy, safety, or convenience profiles.

Conclusion and Recommendations

Cinacalcet was a transformative therapeutic agent, establishing a novel pharmacological class and providing a much-needed medical treatment for severe forms of hyperparathyroidism. Its unique ability to allosterically modulate the Calcium-Sensing Receptor allows for effective, simultaneous control of PTH, calcium, and phosphorus, making it a cornerstone therapy for secondary hyperparathyroidism in dialysis patients and a vital tool for managing hypercalcemia in parathyroid carcinoma and inoperable primary hyperparathyroidism. Its efficacy is well-documented in extensive clinical trials.

However, the clinical use of cinacalcet is governed by a narrow therapeutic window. Its potent calcium-lowering effect creates a significant and ever-present risk of hypocalcemia, which can have severe consequences. Furthermore, its complex pharmacokinetic profile, marked by a profound food effect and its dual role as a substrate and potent inhibitor of CYP enzymes, necessitates a high degree of clinical vigilance to ensure consistent efficacy and avoid dangerous drug-drug interactions. The emergence of the intravenous calcimimetic etelcalcetide has provided an alternative with superior efficacy and guaranteed adherence in the hemodialysis setting, though with a potentially higher risk of hypocalcemia.

Based on this comprehensive analysis, the following recommendations are provided for the safe and effective clinical use of cinacalcet:

1. Strict Adherence to Indications: Cinacalcet should be reserved for the approved patient populations. It is critical to recognize that it is not indicated for CKD patients who are not on dialysis due to the heightened risk of hypocalcemia.
2. Meticulous Initiation and Titration: The "start low, go slow" principle is paramount. Dosing must be initiated at the lowest recommended level and titrated no more frequently than every 2 to 4 weeks, guided by frequent and regular monitoring of serum calcium, phosphorus, and iPTH levels as per guidelines.
3. Proactive Safety Management: Clinicians must maintain a high index of suspicion for hypocalcemia. A clear plan for managing low calcium levels—including dose reduction or interruption, and the use of calcium and vitamin D supplementation—should be in place for every patient. Particular caution is warranted in patients with a history of seizures or cardiac disease.
4. Comprehensive Drug Interaction Screening: Before initiating cinacalcet, a thorough review of the patient's complete medication list is mandatory. Specific attention must be paid to concomitant use of strong CYP3A4 inhibitors (which increase cinacalcet levels) and, most importantly, any CYP2D6 substrates (whose levels will be increased by cinacalcet), especially those with a narrow therapeutic index.
5. Essential Patient Counseling: Patients must be educated on several key points: the absolute necessity of taking the medication with food to ensure proper absorption, the importance of adhering to the prescribed dose without crushing or splitting tablets, how to recognize the symptoms of hypocalcemia and to report them immediately, and the need to avoid interacting substances such as grapefruit juice.

While newer agents are now available, cinacalcet, particularly with the advent of more affordable generic versions, remains a vital and effective medication in the armamentarium against severe disorders of mineral metabolism. Its continued success and safety depend on judicious use by well-informed clinicians who respect its potent pharmacology and adhere to rigorous monitoring protocols.

Works cited

1. Cinacalcet - Wikipedia, accessed July 30, 2025, https://en.wikipedia.org/wiki/Cinacalcet
2. DT-Web: DB01012 - Unict, accessed July 30, 2025, https://alpha.dmi.unict.it/~dtweb/search.php?query=DB01012
3. Cinacalcet | C22H22F3N | CID 156419 - PubChem, accessed July 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cinacalcet
4. Cinacalcet | CAS#226256-56-0 | calcimimetic - MedKoo Biosciences, accessed July 30, 2025, https://www.medkoo.com/products/6453
5. Cinacalcet | 226256-56-0 - Sigma-Aldrich, accessed July 30, 2025, https://www.sigmaaldrich.com/US/en/product/achemblock/adv465749330
6. Buy Online CAS Number 226256-56-0 - TRC - Cinacalcet | LGC Standards, accessed July 30, 2025, https://www.lgcstandards.com/US/en/p/TRC-C441790
7. Sensipar (cinacalcet) Tablets - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021688s013lbl.pdf
8. Clinical Pharmacology Biopharmaceutics Review(s) - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf
9. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride - PubMed, accessed July 30, 2025, https://pubmed.ncbi.nlm.nih.gov/19566113/
10. Cinacalcet Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 30, 2025, https://www.drugs.com/dosage/cinacalcet.html
11. Sensipar Dosage Guide - Drugs.com, accessed July 30, 2025, https://www.drugs.com/dosage/sensipar.html
12. Allosteric Modulation of the Calcium-Sensing Receptor - PMC, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2656812/
13. Cinacalcet hydrochloride - PubMed, accessed July 30, 2025, https://pubmed.ncbi.nlm.nih.gov/15631545/
14. Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody - PMC, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6538321/
15. Cinacalcet - StatPearls - NCBI Bookshelf, accessed July 30, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557658/
16. www.ncbi.nlm.nih.gov, accessed July 30, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557658/#:~:text=Mechanism%20of%20Action,-Cinacalcet%20is%20a&text=%5B11%5D%20Cinacalcet%20functions%20as%20a,decrease%20in%20serum%20calcium%20concentrations.
17. Comparison between cinacalcet and etelcalcetide | Download Table - ResearchGate, accessed July 30, 2025, https://www.researchgate.net/figure/Comparison-between-cinacalcet-and-etelcalcetide_tbl3_323075352
18. Cinacalcet: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, https://go.drugbank.com/drugs/DB01012
19. Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor - Oxford Academic, accessed July 30, 2025, https://academic.oup.com/endo/article/153/3/1232/2423942
20. Pharmacodynamics of Cinacalcet Over 48 Hours in Patients With Controlled Secondary Hyperparathyroidism, accessed July 30, 2025, https://academic.oup.com/jcem/article-pdf/98/4/1718/9048524/jcem1718.pdf
21. Sensipar (cinacalcet hydrochloride) tablets label - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021688s017lbl.pdf
22. Cinacalcet - StatPearls - NCBI Bookshelf, accessed July 30, 2025, https://www.ncbi.nlm.nih.gov/sites/books/NBK557658/
23. Cinacalcet: Side Effects, Uses, Dosage, Interactions, Warnings, accessed July 30, 2025, https://www.rxlist.com/cinacalcet/generic-drug.htm
24. CP.PHAR.61 Cinacalcet (Sensipar) - Superior HealthPlan, accessed July 30, 2025, https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/CP.PHAR.61-10182021.pdf
25. Cinacalcet dosing, indications, interactions, adverse effects, and more, accessed July 30, 2025, https://reference.medscape.com/drug/cinacalcet-342879
26. European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis - Amgen's investor, accessed July 30, 2025, https://investors.amgen.com/news-releases/news-release-details/european-commission-approves-expanded-use-mimparar-cinacalcet/
27. FDA Drug Safety Communication: Pediatric clinical studies of Sensipar (cinacalcet hydrochloride) suspended after report of death, accessed July 30, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-pediatric-clinical-studies-sensipar-cinacalcet-hydrochloride-suspended
28. Cinacalcet: MedlinePlus Drug Information, accessed July 30, 2025, https://medlineplus.gov/druginfo/meds/a605004.html
29. Clinical Policy: Cinacalcet (Sensipar) - NH Healthy Families, accessed July 30, 2025, https://www.nhhealthyfamilies.com/content/dam/centene/NH%20Healthy%20Families/Medicaid/NHPharmacyPT/Final%20CP.PHAR.61%20Cinacalcet%20(Sensipar)%2011.21.17.pdf
30. Cinacalcet Completed Phase 3 Trials for Secondary Hyperparathyroidism (SHPT) / Chronic Kidney Disease (CKD) Treatment - DrugBank, accessed July 30, 2025, https://go.drugbank.com/drugs/DB01012/clinical_trials?conditions=DBCOND0048800%2CDBCOND0054378&phase=3&purpose=treatment&status=completed
31. Study Details | E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events | ClinicalTrials.gov, accessed July 30, 2025, https://clinicaltrials.gov/study/NCT00345839
32. TRANSPARENCY COMMITTEE, accessed July 30, 2025, https://www.has-sante.fr/jcms/c_1775925/fr/mimpara-version-anglaise-ct9634
33. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis | Circulation Research - American Heart Association Journals, accessed July 30, 2025, https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.318556
34. SENSIPAR Product Monograph Page 24 of 26 PART III - Amgen Canada, accessed July 30, 2025, https://www.amgen.ca/en-ca/about/-/media/themes/corporateaffairs/redesign/amgen-ca/amgen-ca/pdf/products/en/en-sensipar-pil.pdf
35. Cinacalcet (Sensipar): Uses & Side Effects - Cleveland Clinic, accessed July 30, 2025, https://my.clevelandclinic.org/health/drugs/19134-cinacalcet-tablets
36. Pharmacogenetic and safety analysis of cinacalcet hydrochloride in healthy Chinese subjects - PMC, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7723585/
37. Cinacalcet Hcl Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed July 30, 2025, https://www.wellrx.com/cinacalcet-hcl/lifestyle-interactions/
38. Indication(s) Intended Population(s) - FDA, accessed July 30, 2025, https://www.fda.gov/files/drugs/published/161_209962-cinacalcet-clinical--bpca.pdf
39. Press Release - SEC.gov, accessed July 30, 2025, https://www.sec.gov/Archives/edgar/data/890465/000119312504039115/dex991.htm
40. Amgen Submitted New Drug Applicatioin for Cinacalcet HCI, accessed July 30, 2025, https://www.amgen.com/newsroom/press-releases/2003/09/amgen-submitted-new-drug-applicatioin-for-cinacalcet-hci
41. Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion for Approval in Europe, accessed July 30, 2025, https://www.amgen.com/newsroom/press-releases/2004/07/mimpara----cinacalcet-hcl----receives-positive-regulatory-opinion-for-approval-in-europe
42. Cinacalcet hydrochloride (Amgen) - PubMed, accessed July 30, 2025, https://pubmed.ncbi.nlm.nih.gov/12811682/
43. Sensipar (cinacalcet) FDA Approval History - Drugs.com, accessed July 30, 2025, https://www.drugs.com/history/sensipar.html
44. Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688 - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm
45. FDA Approves Innovative, First-In-Class Treatment for a Serious Complication of Chronic Kidney Disease - Amgen's investor, accessed July 30, 2025, https://investors.amgen.com/news-releases/news-release-details/fda-approves-innovative-first-class-treatment-serious/
46. Mimpara | European Medicines Agency (EMA), accessed July 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara
47. Public Assessment Report Scientific discussion Cinacalcet Devatis 30 mg, 60 mg and 90 mg film-coated tablets (cinacalcet hydrochloride) NL/H/3388/001-003/DC Date - Geneesmiddeleninformatiebank, accessed July 30, 2025, https://www.geneesmiddeleninformatiebank.nl/pars/h116512.pdf
48. Amgen Release: Mimpara® (cinacalcet) Receives European Commission (EC) Approval for Extension of Marketing Authorisation in the European Union - BioSpace, accessed July 30, 2025, https://www.biospace.com/amgen-release-mimpara-cinacalcet-receives-european-commission-ec-approval-for-extension-of-marketing-authorisation-in-the-b-european-union-b
49. Study Details | Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis | ClinicalTrials.gov, accessed July 30, 2025, https://www.clinicaltrials.gov/study/NCT02138838
50. Study Details | Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism | ClinicalTrials.gov, accessed July 30, 2025, https://clinicaltrials.gov/study/NCT01439867?term=amgen%2020110100&viewType=Table&rank=1
51. Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism | ClinicalTrials.gov, accessed July 30, 2025, https://clinicaltrials.gov/study/NCT01439867
52. Sensipar (cinacalcet) – First-time generic, accessed July 30, 2025, https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/new-generics/newgenerics_sensipar_2019-0314.pdf
53. Cinacalcet Viatris (previously Cinacalcet Mylan) | European Medicines Agency (EMA), accessed July 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-viatris
54. Cinacalcet Mylan - EMA Approval - MedPath, accessed July 30, 2025, https://trial.medpath.com/drug/approvals/ema/2ceb1516653b9621
55. How do cinacalcet and etelcalcetide differ? - PubMed, accessed July 30, 2025, https://pubmed.ncbi.nlm.nih.gov/30009474/
56. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness - PMC, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9142674/
57. Amgen Presents Detailed Data Comparing Etelcalcetide With ..., accessed July 30, 2025, https://www.amgen.com/newsroom/press-releases/2015/11/amgen-presents-detailed-data-comparing-etelcalcetide-with-cinacalcet-in-patients-with-secondary-hyperparathyroidism-receiving-hemodialysis
58. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism A Randomized Clinical Trial - IU Indianapolis ScholarWorks, accessed July 30, 2025, https://scholarworks.indianapolis.iu.edu/bitstream/1805/14394/1/Block_2017_effect2.pdf
59. Incidence of adverse events in head-to-head comparison between cinacalcet and etelcalcetide - ResearchGate, accessed July 30, 2025, https://www.researchgate.net/figure/ncidence-of-adverse-events-in-head-to-head-comparison-between-cinacalcet-and-etelcalcetide_tbl2_325513254
60. What are the alternatives to Cinacalcet (Cinacalcet) for treating hypercalcemia due to gastrointestinal upset? - Dr.Oracle AI, accessed July 30, 2025, https://www.droracle.ai/articles/133453/what-are-the-alternatives-to-cinacalcet-cinacalcet-for-treating-hypercalcemia-due-to-gastrointestinal-upset
61. Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis - Spandidos Publications, accessed July 30, 2025, https://www.spandidos-publications.com/10.3892/etm.2020.9044
62. Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison - Frontiers, accessed July 30, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00040/full
63. Efficacy of low-dose cinacalcet on alternate days for the treatment of ..., accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5304993/